Clinical trial diversity is a balancing act of time, quality, and money
While the topic of clinical trial diversity has been in circulation for some time, it has recently gained traction with…
While the topic of clinical trial diversity has been in circulation for some time, it has recently gained traction with…
Mesoblast has announced that the US Food and Drug Administration (FDA) has accepted a resubmitted biologics license application (BLA) for…
In an evolving drug development landscape, the pace and direction of progress depends on sponsors, outsourcing partners, and investors establishing…
Delix Therapeutics is planning to initiate two studies to evaluate patients with major depression investigating its lead neuroplastogen candidate, DLX-001,…
As biotechs pull resources out of thinner budgets, investors are still being cautious with their investments compared to funding highs…
Running a clinical study is expensive and requires sponsors, vendors, CROs, and sites to move in tandem to ensure trial…
The clinical trial design terrain is evolving. The US Food and Drug Administration (FDA) is trying to increase trial diversity,…
In a complex developmental and regulatory landscape influenced by bureaucracy and contractual timelines, it is more important than ever to…
With the intention of discovering effective and budget-friendly strategies for smooth clinical trial operations, industry leaders, oncology biotechs, and patient…
Alnylam Pharmaceuticals saw shares of its stock jump by 32% after sharing positive topline results for a late-stage study of…